Cousin vs. Sibling Donors in Haplo-HSCT (NCT07662382) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Cousin vs. Sibling Donors in Haplo-HSCT
China1,000 participantsStarted 2026-08-01
Plain-language summary
This observational study aims to emulate a hypothetical pragmatic, multicenter, non-blinded clinical trial enrolling adult patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with grafts derived from either cousin or sibiling donors.
The main research question is whether cousin donor-derived haplo-HSCT is associated with inferior clinical outcomes relative to sibling donor-derived haplo-HSCT.
Study participants consist of adult patients diagnosed with hematological malignancies who underwent cousin or sibiling haplo-HSCT between 2017 and 2024, and all eligible recipients will receive regular follow-up assessments.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients diagnosed with hematological malignancies, including acute leukemia (AL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and non-Hodgkin lymphoma (NHL)
* Receipt of first haploidentical hematopoietic stem cell transplantation between 2017 and 2024
* Documented exact date of transplantation available in medical charts
* Verifiable donor kinship classified as either cousin or sibiling
* Complete longitudinal follow-up data accessible for outcome assessment
Exclusion Criteria:
* Prior receipt of any form of hematopoietic stem cell transplantation
* An age difference of more than 18 years between the donor and recipient
* Failure of successful infusion of donor-derived hematopoietic stem cells following conditioning regimen
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Overall survival
Timeframe: 2 years after transplantation
2
Graft-versus-host disease-free and relapse-free survival
Timeframe: 2 years after transplantation
3
Cumulative incidence of acute graft-versus-host disease
Timeframe: 180 days after transplantation
4
Cumulative incidence of chronic graft-versus-host disease
Timeframe: 2 years after transplantation
Trial details
NCT IDNCT07662382
SponsorThe First Affiliated Hospital of Soochow University